Supplemental Disclosure of Cash Flow and Non-Cash Investing and Financing Activities (Details) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Cash and Cash Equivalents [Line Items]
Cash paid for interest	$ 48,000	$ 36,000	$ 13,000
Income taxes paid	384,000	61,000	0
Purchases of equipment financed through capital leases	0	355,000	85,000
Stock issuance of 167,086 shares in lieu of Directors' fees	0	0	184,000
Stock issuance in lieu of Directors' fees (in shares)		167,086
Deferred financing costs	0	27,000	20,000
Beneficial conversion related to related party	0	0	514,000
Stock issuance in connection with Earn-Out Liability of 1,174,915 shares for 2013 and 2,632,576 shares for 2012	0	5,792,000	3,186,000
Stock issued for earn-out liability (in shares)	1,174,915	2,632,576
Stock issuance in exchange for convertible debt of 5,272,004 shares	0	5,272,000	0
Stock issued for convertible debt (in shares)	5,272,004
Stock issuance of 1,403,630 shares for payment of Line of Credit with related party	0	0	1,403,000
Stock issued during period, shares, issued for payment of Line of Credit with related party (shares)		1,403,630
Stock issuance of 15,958 shares in exchange for services performed	117,000	0	0
Shares issued for services performed (in shares)	15,958
Stock issuance of 216,085 shares for exercise of cashless warrants	0	0	216,000
Shares issued for Cashless Exercise (in shares)		216,085
Stock issuance of 893,267 shares in payment of Convertible Secured Promissory Notes related to acquisition of Surgical Biologics	0	0	893,000
Stock issued related to acquisition of Surgical Biologics (in shares)	893,267	893,267	893,267
Tenant improvement incentive	0	997,000	0
Legal fees paid for public offering	0	102,000	0
Accounts payable
Cash and Cash Equivalents [Line Items]
Legal fees paid for public offering	0	30,000	0
Accrued expenses
Cash and Cash Equivalents [Line Items]
Legal fees paid for public offering	$ 0	$ 62,000	$ 0